● The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.31 for the 2020 fiscal year.
● Over the last seven days, analysts have been revising upwards their EPS estimates for the company.
● Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
● The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
● With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
● Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
● The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 112.23 times its estimated earnings per share for the ongoing year.
● Revenue estimates are regularly revised downwards for the current and coming years.
● For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
● For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
● For the past year, analysts have significantly revised downwards their profit estimates.